Skip to main content

Table 3 P-values of statistical analyses comparing duodenal mRNA levels of selected genes

From: Duodenal mucosal risk markers in patients with familial adenomatous polyposis: effects of celecoxib/ursodeoxycholic acid co-treatment and comparison with patient controls

   Statistical test P-values
KIAA1199 COX-2 CDH1 PPARD GSTA1 CASP3 CCND1 CTNNB1 GSTP1
FAP pre-intervention vs. controls   Mann–Whitney U 0.253 0.021 0.060 0.438 0.008* 0.001* 0.373 0.269 0.104
FAP: pre- vs. post-intervention Group A: celecoxib & UDCA Wilcoxon Signed Rank 0.730 0.826 0.048 0.778 0.272 0.074 0.730 0.272 0.433
Group B: celecoxib & placebo Wilcoxon Signed Rank 0.046 0.345 0.064 0.279 0.173 0.600 0.075 0.101 0.013
Group A vs. B: median of differences Mann–Whitney U 0.048 0.720 0.006* 0.583 0.048 0.128 0.259 0.043 0.019
  1. *Statistically significant with correction for multiple testing applied (p < 0.01).
  2. Abbreviations: FAP, familial adenomatous polyposis; UDCA, ursodeoxycholic acid; COX-2, cyclooxygenase-2; CDH1, E-cadherin type 1; PPARD, peroxisome proliferative activated receptor delta; GSTA1, glutathione S-transferase A1; CASP3, caspase 3; CCND1, cyclin D1; CTNNB1, beta-catenin-1; GSTP1, glutathione S-transferase P1.